

Advanced Lipid Panel with Inflammation

Identify hidden cardiovascular risk using lipid and inflammatory biomarkers

Test description

The risk of developing cardiovascular disease (CVD) has traditionally been assessed by measuring a lipid panel. While it is essential to assess cholesterol concentration levels, measuring the number of apolipoproteins or lipoprotein particles has been shown to better predict CVD.¹⁻³ Inflammation is a critical component of atherosclerotic disease and cardiovascular risk, independent of lipids.⁴ Utilizing inflammation with advanced lipid biomarkers further improves risk stratification.

**Panel components****Lipid Panel**

- Cholesterol, Total
- HDL Cholesterol
- Triglycerides
- Non-HDL and Calculated Components

Apolipoproteins

- Apolipoprotein B
- Lipoprotein (a)

Lipoprotein Fractionation, Ion Mobility

- LDL Particle Number
- LDL Small
- LDL Medium
- HDL Large
- LDL Pattern
- LDL Peak Size

Inflammation

- hs-CRP
- Lp-PLA₂ Activity

Individuals suitable for testing

- Individuals with 1 or more risk factors for the development of CVD
- Individuals prone to lipid discordance including those with obesity, hypertriglyceridemia, diabetes or metabolic syndrome, and individuals taking lipid lowering therapies^{5,6}
- Personal or family history of premature atherosclerotic cardiovascular disease (ASCVD), familial hypercholesterolemia, or Lp(a) excess⁷
- Individuals at borderline risk (5%–<7.5% 10-year ASCVD risk) or intermediate risk (≥7.5%–<20% 10-year ASCVD risk)



50% of patients hospitalized with coronary artery disease
have 'normal' cholesterol levels⁸

Enhanced, detailed reporting



Results are displayed in a clear, enhanced report for ease of interpretation



The Advanced Lipid Panel with Inflammation improves risk stratification, allowing you to personalize patient treatment plans by more precisely:

- Setting therapeutic diet, exercise, and smoking cessation goals
- Initiating or intensifying lipid lowering therapies
- Evaluating metabolic dysfunction as a potential driver for lipid and inflammatory abnormalities
- Identifying opportunities for adjunct therapies

Ask your Cardiometabolic account executive for detailed information on each analyte.

Test Name	Test Code	CPT Code ^a	Preferred Specimen(s)
Advanced Lipid Panel with Inflammation	94220	80061, 83704, 82172, 83695, 86141, 83698	Serum
Advanced Lipid Panel	92145	80061, 83704, 82172, 83695	Serum

^aThe CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.



Assess cardiovascular disease risk using the Advanced Lipid Panel with Inflammation.

For more information, contact your Cardiometabolic account executive.

Panel components may be ordered separately.

Advanced Lipid Panel with Inflammation: Cholesterol, Total (91717); HDL Cholesterol (91719); Triglycerides (91718); Non-HDL and Calculated Components; Lipoprotein Fractionation, Ion Mobility (91604); Apolipoprotein B (91726); Lipoprotein (a) (91729); hs-CRP (91737); Lp-PLA2 Activity (94218)

Advanced Lipid Panel: Cholesterol, Total (91717); HDL Cholesterol (91719); Triglycerides (91718); Non-HDL and Calculated Components; Lipoprotein Fractionation, Ion Mobility (91604); Apolipoprotein B (91726); Lipoprotein (a) (91729)

References

- Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. *Circ Cardiovasc Qual Outcomes*. 2011;4(3):337-345. doi:10.1161/CIRCOUTCOMES.110.959247
- Marston NA, Giugliano RP, Melloni GEM, et al. Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: Distinguishing between particle concentration, type, and content. *JAMA Cardiol*. 2022;7(3):250-256. doi:10.1001/jamacardio.2021.5083
- Cole TG, Contois JH, Csako G, et al. Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices. *Clin Chem*. 2013;59(5):752-770. doi:10.1373/clinchem.2012.196733
- Ridker PM, MacFadyen JG, Everett BM, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. *Lancet*. 2018;391(10118):319-328. doi:10.1016/S0140-6736(17)32814-3
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J*. 2019;41(1). doi:10.1093/eurheartj/ehz455
- Johannessen C, Mortensen M, Langsted A, Nordestgaard B. Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients. *J Am Coll Cardiol*. 2021;77(11):1439-1450. doi:10.1016/j.jacc.2021.01.027
- Virani SS, Koschinsky ML, Maher L, et al. Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know. *Prog Cardiovasc Dis*. 2022;73:32-40. doi:10.1016/j.pcad.2022.01.002
- Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. *Am Heart J*. 2009;157(1):111-117.e2. doi:10.1016/j.ahj.2008.08.010

QuestDiagnostics.com

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. ©2022 Quest Diagnostics Incorporated. All rights reserved. MI11754 12/2022

